Celldex Therapeutics, Inc.
CLDX
$27.81
$1.144.27%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -45.73% | -32.88% | -23.45% | -11.62% | -23.65% |
| Total Depreciation and Amortization | 8.53% | 7.97% | 6.93% | 5.62% | 6.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 68.03% | 51.64% | 17.23% | 4.76% | 3.00% |
| Change in Net Operating Assets | 153.76% | -295.06% | -542.31% | -260.46% | -380.79% |
| Cash from Operations | -13.71% | -53.25% | -43.69% | -47.06% | -63.53% |
| Capital Expenditure | -19.68% | -59.20% | -16.68% | -5.56% | -31.87% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 137.20% | 132.10% | 114.80% | -177.22% | -593.48% |
| Cash from Investing | 136.61% | 131.57% | 114.37% | -174.27% | -602.46% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.78% | -99.71% | -99.15% | 102.07% | 26,460.59% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.78% | -99.71% | -99.15% | 102.07% | 26,460.59% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -102.37% | -235.69% | -260.68% | -219.93% | 498.39% |